DropGenie Raises $5 Million for Lab Automation Tech
The startup plans to launch its microfluidics-based automated laboratory workflow system in the second quarter of 2027.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Do you support increased investment in biotech startups aiming to automate drug discovery processes?
DropGenie has secured $5 million USD ($7 million CAD) in a seed-plus financing round led by Skeleton Key. The company is developing digital microfluidics technology to automate lab workflows for the pharmaceutical sector.
Why it matters
The company’s technology enables drug research using up to 100 times fewer cells and reagents than traditional methods, potentially lowering R&D costs. This capital supports development ahead of a planned commercial launch.
DropGenie’s platform utilizes digital microfluidics to manipulate liquid volumes on a chip using electrical signals. The system achieves a 100-fold reduction in reagent and cell requirements compared to standard manual laboratory benchmarks.
The players
DropGenie
A biotech startup based in Montréal and Boston developing digital microfluidics platforms for automated laboratory research.
Skeleton Key
A venture capital firm that led the current $5 million USD seed-plus financing round.
The details
Digital microfluidics uses an array of electrodes to move, split, and merge individual liquid droplets across a printed circuit board. By applying specific electrical potentials to the surface, the device controls droplet movement, enabling the automation of precise laboratory tasks without mechanical pumps or valves. DropGenie applies this architecture to high-throughput screening and research workflows.
Timeline
2018: DropGenie was founded.
October 26, 2026: DropGenie announced the financing round.
Q2 2027: Planned commercial launch of automated lab workflows.
The Tech Race
DropGenie follows the industry trend of increasing research efficiency set by the 2013 application of CRISPR gene-editing technology. The company faces a crowded field of automated laboratory startups competing to minimize resource waste in drug discovery.
The firm’s automated workflows will reach pharmaceutical researchers and developers by mid-2027. Existing partnerships with organizations like AbbVie and UCB Pharma suggest these tools will be integrated into large-scale drug discovery pipelines first.
The takeaway
DropGenie’s ability to scale down reagent usage by two orders of magnitude marks a significant shift in resource-intensive lab workflows. Investors and researchers should watch for the commercial platform’s performance benchmarks in Q2 2027 to see if it delivers on its efficiency promises.
What happens next
DropGenie plans to move its digital microfluidics platform to a commercial launch in the second quarter of 2027.
Further reading
Explore more developments in Biotech to track the future of automated drug discovery research.
Live Poll
Do you support increased investment in biotech startups aiming to automate drug discovery processes?
